Surfactant protein D inhibits activation of non-small cell lung cancer-associated mutant EGFR and affects clinical outcomes of patients

Extracellular region of epidermal growth factor receptor: a potential target for anti-EGFR drug discovery

(2016) A Dokala et al.   ONCOGENE

Correlation between Efficacy of the EGFR Tyrosine Kinase Inhibitor and Serum Tumor Markers in Lung Adenocarcinoma Patients

(2016) Jin Pan et al.   Clinical Laboratory

A Structural Perspective on the Regulation of the Epidermal Growth Factor Receptor

(2015) Erika Kovacs et al.   Annual Review of Biochemistry

Pretreatment levels of the serum biomarkers CEA, CYFRA 21–1, SCC and the soluble EGFR and its ligands EGF, TGF-alpha, HB-EGF in the prediction of outcome in erlotinib treated non-small-cell lung cancer patients

(2015) Elena Yaiza Romero-Ventosa et al.   SpringerPlus

ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics

(2014) Carlos L. Arteaga et al.   CANCER CELL

Therapeutic Strategies Utilized in the Setting of Acquired Resistance to EGFR Tyrosine Kinase Inhibitors

(2014) H. A. Yu et al.   CLINICAL CANCER RESEARCH

Surfactant protein D suppresses lung cancer progression by downregulation of epidermal growth factor signaling

(2014) Y Hasegawa et al.   ONCOGENE

Cetuximab Response of Lung Cancer-Derived EGF Receptor Mutants Is Associated with Asymmetric Dimerization

(2013) J. Cho et al.   CANCER RESEARCH

Suppression of Heregulin β Signaling by the SingleN-Glycan Deletion Mutant of Soluble ErbB3 Protein

(2013) Motoko Takahashi et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

EGF shifts human airway basal cell fate toward a smoking-associated airway epithelial phenotype

(2013) R. Shaykhiev et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Mechanism for activation of mutated epidermal growth factor receptors in lung cancer

(2013) M. Red Brewer et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Association Between Genetic Variations In Surfactant Protein D and Emphysema, Interstitial Pneumonia, and Lung Cancer in a Japanese Population

(2012) Takeo Ishii et al.   COPD-Journal of Chronic Obstructive Pulmonary Disease

Pivotal role of epithelial cell adhesion molecule in the survival of lung cancer cells

(2011) Tetsunari Hase et al.   CANCER SCIENCE

Serum levels of surfactant protein D predict the anti-tumor activity of gefitinib in patients with advanced non-small cell lung cancer

(2010) Hiroyuki Yamaguchi et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Pulmonary Collectins Protect Macrophages against Pore-forming Activity ofLegionella pneumophilaand Suppress Its Intracellular Growth

(2010) Kaku Sawada et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

(2010) Makoto Maemondo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

(2009) Tetsuya Mitsudomi et al.   LANCET ONCOLOGY

Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors

(2009) A F Gazdar   ONCOGENE

Structure-Based View of Epidermal Growth Factor Receptor Regulation

(2008) Kathryn M. Ferguson   Annual Review of Biophysics

Vascular Endothelial Growth Factor Receptor-1 Contributes to Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Cancer Cells

(2008) R. Bianco et al.   CLINICAL CANCER RESEARCH

Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer

(2008) J. A. Engelman et al.   CLINICAL CANCER RESEARCH

Pulmonary Surfactant Protein D Inhibits Lipopolysaccharide (LPS)-induced Inflammatory Cell Responses by Altering LPS Binding to Its Receptors

(2008) Masami Yamazoe et al.   JOURNAL OF BIOLOGICAL CHEMISTRY